top of page
AI pixabay huge.jpg

Digital Biomarkers: Current Limitations and Future Outlook

There’s an undeniable push to drive innovation for a new age of precision medicine. At the 2021 Digital Biomarkers & Digital Measurements Summit, Kate Lyden, VivoSense Chief Science Officer, joined a panel of experts to discuss the future of digital biomarkers and advancing medicine toward a patient-oriented, decentralized, tech-enabled approach. Here is a quick snap-shot of her key takeaways.


Current Limitations of Digital Biomarkers

The biggest barrier to the widespread adoption of digital biomarkers is the lack of validity evidence to support them both from a clinical and analytical perspective. For example, how well a real-world measure of physical function correlates with the in-clinic six-minute walk test doesn’t prove it is fit-for-purpose. Researchers must uncover how digital measures are clinically relevant to the patient population survival, hospitalization, or other hard clinical outcomes. We need to continue building the validity evidence base for all digital measures moving forward.


The Future of Digital Biomarkers

Digital clinical measures have the potential to significantly advance patient-centric approaches to health, including patient-focused drug development and precision medicine. They have the ability to continuously and passively capture real-world data that is both clinically relevant and meaningful to patients.


For digital clinical measures to realize their potential, we must curate contextually rich datasets that integrate data from multiple sources including, wearable and remote monitoring technologies, patient reports, and EHR’s. Our ability to leverage these data into actionable insights will further depend on the development of systems and processes to integrate, interpret, and communicate their meaning to all stakeholders along the healthcare continuum.




Comments


bottom of page